Skip to Content

Posts tagged with "“Me Too” Drugs"

  • "Me Too" Drugs

  • "Me Too" Drugs

    Blurry Copies

    Via Tyler Cowen at Marginal Revolution, I came across this editorial by John Gapper in the Financial Times on me-too drugs. Its points will be familiar to readers of this blog: “If there is one product that annoys people, it is the me-too drug. Pharmaceuticals companies should take advantage of the genetics revolution to find… Read More
  • "Me Too" Drugs

    The Last Word (For A While) On Me-Too Drugs

    What sort of markets breed multiple therapies? The ones with the largest number of potential (paying) patients, for one thing, which shouldn’t surprise anyone. Fortunately, that also corresponds pretty well with the markets that could be better served with another drug. The success of the first compound in a new market shows that it can… Read More
  • "Me Too" Drugs

    Me Too, Part Two

    As came up in the comments to the previous post, there’s not as much price competition inside a given drug category as you’d think. That’s not because we’re Evil Price Gougers, at least not necessarily. As I was pointed out yesterday, “me-too” type drugs aren’t as equivalent as some people think. The main r… Read More
  • "Me Too" Drugs

    Clinical Trials And What to Do With Them

    Allow me to get a little defensive. If I understand some of the critics of my industry, we spend most of our time making “me-too” ripoff drugs rather than doing something that provides any clinical benefit to patients. And, if I have this right, here’s how we determine efficacy: we run clinical studies until we… Read More
  • "Me Too" Drugs

    Hypertension and Marketing

    There were plenty of stories in the press today about the ALLHAT study, which showed that diuretics are still the most effective way to treat hypertension in most people. Let me say right off that I really like this kind of study, and I think that there should be more of them (more on this… Read More
  • "Me Too" Drugs

    Merck and Its Competition

    There’s an interesting interview up at Business Week’s site with Anthony Ford-Hutchinson, a Merck research honcho. Much of the interview is routine: “How’s the new drug for XYZ coming along?” “Why, just fine!” But he does get in a few good cuts: Q: How would you describe the culture of Merck’s researc… Read More
  • "Me Too" Drugs

    Our Buddies at the FDA

    Another question I’ve had posed to me is whether the FDA standards for drug approval are too tight (no one who writes to me seems to worry that they might be too loose, although you can find groups who’d argue just that.) Overall, I don’t think so. There are really two sets of standards, for… Read More
  • "Me Too" Drugs

    Adam Smith Goes Pharmaceutical

    As readers will have noted in my comments on drugs like Clarinex and Nexium, I certainly don’t think the industry I work in is always a one-hundred-percent benefactor of humanity. Drug companies are here to make money, and (like any business) they’re trying to make the most money they can, consistent with their tolerance for… Read More
  • "Me Too" Drugs

    Innovation and Its Discontents

    Yesterday’s report on pharmaceutical cost and innovation got a lot of play in the media, including the ABC special last night (which I didn’t see much of.) I’m of two minds about it: there’s some truth in it, but there are important things that it misses. Companies will do everything they can think of to… Read More
...234